{"id":390557,"date":"2018-11-12T00:00:00","date_gmt":"2018-11-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2018-biopharma-colorectal-cancer-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-05-03T23:37:22","modified_gmt":"2026-05-03T23:37:22","slug":"dlsfon0002-2018-biopharma-colorectal-cancer-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2018-biopharma-colorectal-cancer-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Colorectal Cancer | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival\u00a0of 65.1%. Current treatment for metastatic colorectal cancer is dominated by chemotherapy regimens in combination with angiogenesis inhibitors and\u00a0EGFR\u00a0inhibitors. Several areas of high unmet need\u2014notably,\u00a0<em>RAS<\/em>-mutant patient populations\u2014offer significant commercial opportunity for innovative agents. Although sales of immune checkpoint inhibitors and emerging\u00a0BRAF\/MEK\u00a0inhibitor combinations will increase over the 2017-2027 forecast period, generic and biosimilar competition will also have a major impact on therapy sales. This report provides insight on how treatment options for colorectal cancer are likely to change over the 2017-2027 forecast period. It also analyzes the current and future earnings potential of drugs already in the market and those expected to be approved for colorectal cancer.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<p>We forecast that sales of colorectal cancer therapies will decline over the 2017-2027 study period.\u00a0<strong>What will be the major constraints on therapy sales? What are the key drivers of growth over this period? What are the drug development activities of note? What challenges and opportunities remain?<\/strong><\/p>\n<p>Two\u00a0BRAF\/MEK\u00a0inhibitors combinations\u2014Mektovi\/Braftovi\/Erbitux and Zelboraf\/Erbitux\/irinotecan\u2014have shown promising efficacy in\u00a0<em>BRAF<\/em>-mutant colorectal cancer patients.\u00a0<strong>What is thought-leader opinion of these agents and of this drug class? For which patient populations will these agents be positioned? Will these agents receive approval in the markets under study? How will use of these agents affect prescribing of other agents for colorectal cancer?<\/strong><\/p>\n<p>In 2017, the\u00a0FDA\u00a0approved Keytruda (Merck) and Opdivo (Bristol-Myers Squibb) for second- and later-line treatment of\u00a0MSI-H\/dMMR\u00a0colorectal cancer that is refractory to a fluoropyrimidine, irinotecan, and oxaliplatin. In 2018, Opdivo plus low-dose Yervoy received\u00a0FDA\u00a0approval in the same setting.\u00a0<strong>How do key opinion leaders perceive these therapies? Will these therapies receive label expansions across the G7? Which other immune checkpoint inhibitors are being developed and in which patient populations?<\/strong><\/p>\n<p>Retrospective analyses of clinical trials with Avastin and\u00a0EGFR\u00a0inhibitors have shown that the side on which the tumor is located could be a prognostic factor for response to these agents.\u00a0<strong>How do key opinion leaders view these data? Will \u201csidedness\u201d have an impact on the treatment of metastatic colorectal cancer over the forecast period?<\/strong><\/p>\n<p><strong>Scope:<\/strong><\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research:<\/strong>\u00a020 country-specific interviews with thought leaders.<\/p>\n<p><strong>Epidemiology:\u00a0<\/strong>Diagnosed incident cases of stage I, II, III , and IV colorectal cancer.<\/p>\n<p><strong>Population segments in market forecast<\/strong>:Stage II colon cancer;stage II rectal cancer;stage III colon cancer;stage III rectal cancer;stage\u00a0IV\u00a0colorectal cancer wild-type\u00a0<em>BRAF<\/em>\u00a0and\u00a0<em>RAS,<\/em>first-line (left-sided);stage\u00a0IV\u00a0colorectal cancer wild-type\u00a0<em>BRAF<\/em>\u00a0and\u00a0<em>RAS,<\/em>\u00a0first-line (right-sided);stage\u00a0IV\u00a0colorectal cancer mutant\u00a0<em>RAS,<\/em>\u00a0first-line;stage\u00a0IV\u00a0colorectal cancer mutant\u00a0<em><em>BRAF<\/em>,<\/em>\u00a0first-line;stage\u00a0IV\u00a0colorectal cancer wild-type\u00a0<em>BRAF<\/em>\u00a0and\u00a0<em>RAS,<\/em>second-line (left-sided); stage\u00a0IV\u00a0colorectal cancer wild-type\u00a0<em>BRAF<\/em>\u00a0and\u00a0<em>RAS,<\/em>second-line (right-sided); stage\u00a0IVcolorectal cancer mutant\u00a0<em>RAS<\/em>, second-line; stage\u00a0IV\u00a0colorectal cancer mutant\u00a0<em><em>BRAF<\/em><\/em>, second-line; stage\u00a0IV\u00a0colorectal cancer wild-type\u00a0<em>BRAF<\/em>\u00a0and\u00a0<em>RAS<\/em><em>,<\/em>\u00a0third-line (left-sided); stage\u00a0IV\u00a0colorectal cancer wild-type\u00a0<em>BRAF<\/em>\u00a0and\u00a0<em>RAS<\/em><em>,<\/em>\u00a0third-line (right-sided); stage\u00a0IVcolorectal cancer mutant\u00a0<em>RAS,<\/em>\u00a0third-line; stage IV colorectal cancer mutant\u00a0<em><em>BRAF<\/em><\/em>.<\/p>\n<p><strong>Emerging therapies:<\/strong>\u00a0Phase III: 12 drugs; Phase II: 26 drugs; Phase I: 14 drugs.<\/p>\n","protected":false},"template":"","class_list":["post-390557","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390557\/revisions"}],"predecessor-version":[{"id":393681,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390557\/revisions\/393681"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}